We are thrilled to announce the latest work from the BLOODPAC MRD Strategic Steering Group
BLOODPAC shared a post on LinkedIn about a recent paper by Andrew G. Hadd et al. published in Clinical and Transitional Science:
“We are thrilled to announce the latest work from the BLOODPAC Molecular Residual Disease (MRD) Strategic Steering Group, now published in Clinical Translational Science entitled Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium
Liquid biopsy holds immense promise for assessing MRD in solid tumors, but inconsistent terminology poses challenges in communication, collaboration, and clinical implementation. This new publication establishes a standardized lexicon for MRD assessment, particularly focusing on circulating tumor DNA (ctDNA) detection.
Developed through a rigorous, multi-stakeholder effort, this lexicon is a critical step toward improving clarity, reproducibility, and integration of MRD testing in research and clinical applications.
Check out the full publication here.”
Authors: Andrew G. Hadd et al.
Diana Merino Vega, Senior Director Cancer Biomarker Development at AstraZeneca, shared BLOODPAC’s post, adding:
“Creating a common language is so crucial to ensuring appropriate adoption and facilitating the use of innovative technologies.
In the BLOODPAC’s Molecular Residual Disease (MRD) Strategic Steering Group, we took it upon ourselves to carefully define and achieve agreement on terms in the burgeoning field of liquid biopsies
Congratulations to all those involved, and a special congratulations to Angela Silvestro and Andrew Hadd for leading us and getting us to the finish line”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023